CORCEPT THERAPEUTICS INC Net Income (Loss) Available to Common Stockholders, Diluted
CORCEPT THERAPEUTICS INC (CORT) reported Net Income (Loss) Available to Common Stockholders, Diluted of $42.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $42.14M, a 21.76% increase year-over-year.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$31.20M, a 253.80% decline year-over-year.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $23.90M, a 21.34% decline year-over-year.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $19.36M, a 58.54% decline year-over-year.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2025 was $98.17M, a 29.74% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2024 was $139.73M, a 32.45% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2023 was $105.50M, a 4.15% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2022 was $101.29M, a 9.98% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.14M 10-Q · filed 2026-07-29 | $11.02M 10-Q · filed 2026-07-29 | $34.84M derived: sum of 3 quarters · filed 2026-07-29 | $54.20M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$31.20M 10-Q · filed 2026-04-30 | -$7.30M derived: sum of 2 quarters · filed 2026-04-30 | $12.06M derived: sum of 3 quarters · filed 2026-04-30 | $46.67M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.26M derived: sum of 2 quarters · filed 2026-02-24 | $77.87M derived: sum of 3 quarters · filed 2026-07-29 | $98.17M 10-K · filed 2026-02-24 |
| 2025-09-30 | $19.36M 10-Q · filed 2025-11-04 | $53.97M derived: sum of 2 quarters · filed 2026-07-29 | $74.27M 10-Q · filed 2025-11-04 | $104.65M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $34.61M 10-Q · filed 2026-07-29 | $54.92M 10-Q · filed 2026-07-29 | $85.29M derived: sum of 3 quarters · filed 2026-07-29 | $131.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $20.29M 10-Q · filed 2026-04-30 | $50.68M derived: sum of 2 quarters · filed 2026-04-30 | $97.37M derived: sum of 3 quarters · filed 2026-04-30 | $132.49M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $30.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $77.08M derived: sum of 2 quarters · filed 2026-02-24 | $112.20M derived: sum of 3 quarters · filed 2026-02-24 | $139.73M 10-K · filed 2026-02-24 |
| 2024-09-30 | $46.69M 10-Q · filed 2025-11-04 | $81.81M derived: sum of 2 quarters · filed 2025-11-04 | $109.34M 10-Q · filed 2025-11-04 | $140.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $35.12M 10-Q · filed 2025-07-31 | $62.64M 10-Q · filed 2025-07-31 | $93.78M derived: sum of 3 quarters · filed 2026-02-24 | $124.95M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $27.51M 10-Q · filed 2025-05-05 | $58.66M derived: sum of 2 quarters · filed 2026-02-24 | $89.83M derived: sum of 3 quarters · filed 2026-02-24 | $117.19M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $31.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $62.31M derived: sum of 2 quarters · filed 2026-02-24 | $89.67M derived: sum of 3 quarters · filed 2026-02-24 | $105.50M 10-K · filed 2026-02-24 |
| 2023-09-30 | $31.17M 10-Q · filed 2024-10-30 | $58.53M derived: sum of 2 quarters · filed 2024-10-30 | $74.35M 10-Q · filed 2024-10-30 | $90.87M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $27.36M 10-Q · filed 2024-07-29 | $43.17M 10-Q · filed 2024-07-29 | $59.70M derived: sum of 3 quarters · filed 2025-02-26 | $94.25M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $15.81M 10-Q · filed 2024-05-01 | $32.34M derived: sum of 2 quarters · filed 2025-02-26 | $66.89M derived: sum of 3 quarters · filed 2025-02-26 | $94.29M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $16.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $51.08M derived: sum of 2 quarters · filed 2025-02-26 | $78.48M derived: sum of 3 quarters · filed 2025-02-26 | $101.29M 10-K · filed 2025-02-26 |
| 2022-09-30 | $34.55M 10-Q · filed 2023-11-01 | $61.95M derived: sum of 2 quarters · filed 2023-11-01 | $84.75M 10-Q · filed 2023-11-01 | $116.80M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $27.40M 10-Q · filed 2023-08-02 | $50.20M 10-Q · filed 2023-08-02 | $82.25M derived: sum of 3 quarters · filed 2024-02-15 | $112.72M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $22.80M 10-Q · filed 2023-05-03 | $54.85M derived: sum of 2 quarters · filed 2024-02-15 | $85.32M derived: sum of 3 quarters · filed 2024-02-15 | $111.84M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $62.52M derived: sum of 2 quarters · filed 2024-02-15 | $89.05M derived: sum of 3 quarters · filed 2024-02-15 | $112.51M 10-K · filed 2024-02-15 |
| 2021-09-30 | $30.47M 10-Q · filed 2022-11-03 | $56.99M derived: sum of 2 quarters · filed 2022-11-03 | $80.46M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $26.52M 10-Q · filed 2022-08-04 | $49.99M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $106.01M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |